Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term lubiprostone safety, efficacy, and pharmacokinetics in pediatric functional constipation
NL-OMON41677Phase 3Active, not recruiting
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cobiprostone in functional constipation (FC) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Incidence of adverse events, Change from baseline in clinical laboratory parameters and 14 more. Started Mar 2015; status: active, not recruiting.
02
Drugs
cobiprostone
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on NL-OMON41677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41677.